Terms: = Breast cancer AND PR, PGR, progesterone receptor AND Prognosis
3042 results:
1. The evolvement of breast cancer therapies: What we have done and where all these head off.
Nurlaila I; Pambudi S
Saudi Med J; 2024 Apr; 45(4):331-340. PubMed ID: 38657992
[TBL] [Abstract] [Full Text] [Related]
2. Log odds of positive lymph nodes (LODDS)-based novel nomogram for survival estimation in patients with invasive micropapillary carcinoma of the breast.
Meng X; Hao F; Wang N; Qin P; Ju Z; Sun D
BMC Med Res Methodol; 2024 Apr; 24(1):90. PubMed ID: 38637725
[TBL] [Abstract] [Full Text] [Related]
3. The HLA-I landscape confers prognosis and antitumor immunity in breast cancer.
Ding XH; Xiao Y; Chen F; Liu CL; Fu T; Shao ZM; Jiang YZ
Brief Bioinform; 2024 Mar; 25(3):. PubMed ID: 38602320
[TBL] [Abstract] [Full Text] [Related]
4. Significance of Estrogen/progesterone receptor Expression in Metaplastic breast Carcinoma.
Hashmi AA; Mallick BA; Rashid K; Malik UA; Zia S; Zia F; Irfan M
Dis Markers; 2024; 2024():2540356. PubMed ID: 38601434
[TBL] [Abstract] [Full Text] [Related]
5. Effect of tumor-infiltrating immune cells (mast cells, neutrophils and lymphocytes) on neoadjuvant chemotherapy response in breast carcinomas.
Okcu O; Öztürk Ç; Yalçın N; Yalçın AC; Şen B; Aydın E; Öztürk AE
Ann Diagn Pathol; 2024 Jun; 70():152301. PubMed ID: 38581761
[TBL] [Abstract] [Full Text] [Related]
6. Comparison of neoadjuvant chemotherapy response and prognosis between HR-low/HER2-negative BC and TNBC: an exploratory real-world multicentre cohort study.
Peng J; Hong Y; Chen Q; Xu F; Zhang D; Yao J; Zou Q; Yuan L; Li L; Long Q; Liao L; Liu M; Liu X; Wang S; Yi W
Front Endocrinol (Lausanne); 2024; 15():1347762. PubMed ID: 38567311
[TBL] [Abstract] [Full Text] [Related]
7. The correlation study between TOP2A gene expression in circulating tumor cells and chemotherapeutic drug resistance of patients with breast cancer.
Ye JH; Yu J; Huang MY; Mo YM
Breast Cancer; 2024 May; 31(3):417-425. PubMed ID: 38561479
[TBL] [Abstract] [Full Text] [Related]
8. [Clinicopathological characteristics and immune microenvironment of breast squamous cell carcinoma].
Liang JY; Wang YM; Wen Z; Zhang WH; Gao ZZ; Wang Z; Guo SP
Zhonghua Bing Li Xue Za Zhi; 2024 Apr; 53(4):337-343. PubMed ID: 38556816
[No Abstract] [Full Text] [Related]
9. Outcomes of the patients with metastatic male breast cancer.
Dogan I; Khanmammadov N; Ozkurt S; Aydiner A; Saip P
J Cancer Res Ther; 2024 Jan; 20(1):98-102. PubMed ID: 38554305
[TBL] [Abstract] [Full Text] [Related]
10. Potential Value of HSP90α in prognosis of Triple-Negative breast cancer.
Wang HF; Chen Y; Cao B; Pei J
Med Sci Monit; 2024 Mar; 30():e943049. PubMed ID: 38553816
[TBL] [Abstract] [Full Text] [Related]
11. Case report: A case of Paget disease outside the axillary breast.
Zhou Z; Zhou B; Wu X; Wei W
Medicine (Baltimore); 2024 Mar; 103(13):e37541. PubMed ID: 38552095
[TBL] [Abstract] [Full Text] [Related]
12. Association of hormone receptors and human epidermal growth factor receptor-2/neu expressions with clinicopathologic factors of breast carcinoma: a cross-sectional study in a tertiary care hospital, Kabul, Afghanistan.
Esmat E; Haidary AM; Saadaat R; Rizvi SN; Aleena S; Haidari M; Hofiani SMS; Hussaini N; Hakimi A; Khairy A; Abdul-Ghafar J
BMC Cancer; 2024 Mar; 24(1):388. PubMed ID: 38539179
[TBL] [Abstract] [Full Text] [Related]
13. Clinical significance of low expression of CADM3 in breast cancer and preliminary exploration of related mechanisms.
Ren H; Wang Z; Zhang L; Zhu G; Li F; Chen B
BMC Cancer; 2024 Mar; 24(1):367. PubMed ID: 38515057
[TBL] [Abstract] [Full Text] [Related]
14. Comprehensive evaluation of the relationship between biomarker profiles and neoadjuvant chemotherapy outcomes for breast cancer patients.
Wang M; Wei Z; Kong J; Zhao H
Diagn Pathol; 2024 Mar; 19(1):53. PubMed ID: 38509525
[TBL] [Abstract] [Full Text] [Related]
15. [A Case of breast cancer That Developed Pulmonary Tumor Thrombotic Microangiopathy during Adjuvant Chemotherapy].
Okano K; Suzuki T; Abe A; Itaya A; Kameyama Y; Matsumoto S; Hakamada K
Gan To Kagaku Ryoho; 2024 Mar; 51(3):283-285. PubMed ID: 38494809
[TBL] [Abstract] [Full Text] [Related]
16. PIK3CA mutation-driven immune signature as a prognostic marker for evaluating the tumor immune microenvironment and therapeutic response in breast cancer.
Ren X; Cui H; Dai L; Chang L; Liu D; Yan W; Zhao X; Kang H; Ma X
J Cancer Res Clin Oncol; 2024 Mar; 150(3):119. PubMed ID: 38466449
[TBL] [Abstract] [Full Text] [Related]
17. Correlation between postoperative treatment selection and prognosis determined using the Oncotype DX® test data: a retrospective multicenter study in Japan.
Tsuchida Y; Niikura N; Chishima T; Mizuno M; Kawate T; Fuchikami H; Miyoshi Y; Sakai T; Kotani H; Kondo N; Hayashi N
Breast Cancer; 2024 May; 31(3):401-408. PubMed ID: 38451415
[TBL] [Abstract] [Full Text] [Related]
18. Overexpression of malic enzyme is involved in breast cancer growth and is correlated with poor prognosis.
Hu WC; Yang YF; Cheng CF; Tu YT; Chang HT; Tsai KW
J Cell Mol Med; 2024 Mar; 28(6):e18163. PubMed ID: 38445776
[TBL] [Abstract] [Full Text] [Related]
19. Risk factors and prognosis of sentinel lymph node metastasis in breast-conserving breast cancer: A retrospective study based on the SEER database.
Liu R; Chen J; Cao W; Li T; Liao Y; Li Y
Medicine (Baltimore); 2024 Mar; 103(9):e37263. PubMed ID: 38428869
[TBL] [Abstract] [Full Text] [Related]
20. [Clinical characteristics and prognostic factors of breast cancer patients with tumor deposits in the ipsilateral axillary region].
Xiao JJ; Huang ML; Yan CJ; Ling R; Wei HL
Zhonghua Zhong Liu Za Zhi; 2024 Feb; 46(2):146-154. PubMed ID: 38418189
[No Abstract] [Full Text] [Related]
[Next]
